Sonoma Pharmaceuticals In... (SNOA)
NASDAQ: SNOA
· Real-Time Price · USD
4.61
-0.10 (-2.12%)
At close: Sep 03, 2025, 3:59 PM
-2.12% (1D)
| Bid | 4.51 |
| Market Cap | 7.58M |
| Revenue (ttm) | 14.91M |
| Net Income (ttm) | -3.56M |
| EPS (ttm) | -2.21 |
| PE Ratio (ttm) | -2.09 |
| Forward PE | -3.57 |
| Analyst | n/a |
| Ask | 4.97 |
| Volume | 54,484 |
| Avg. Volume (20D) | 1,303,335 |
| Open | 4.61 |
| Previous Close | 4.71 |
| Day's Range | 4.59 - 4.77 |
| 52-Week Range | 1.75 - 6.92 |
| Beta | 1.26 |
About SNOA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SNOA
Website n/a
Next Earnings Release
Sonoma Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+72.79%
Sonoma Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
3 weeks ago
+1.67%
Sonoma Pharmaceuticals shares are trading higher after the company launched a HOCI-based diaper rash product in 3,600 Walmart stores and online.
3 weeks ago · accessnewswire.com
Sonoma Pharmaceuticals Reports First Fiscal Quarter 2026 Financial ResultsRevenues increased 18% compared to same period last year U.S. revenue increased 57% compared to same period last year Net loss per share decreased 43% compared to same period last year BOULDER, COLORA...
2 months ago · accessnewswire.com
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial ResultsRevenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024 Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024 EBITDA loss im...